Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 2/2020

01-02-2020 | Metastasis | Melanoma

Sentinel Node Biopsy for Melanoma Patients with a Local Recurrence or In-Transit Metastasis

Authors: Amanda A. G. Nijhuis, MD, Ivan D. de A. O. Santos Filho, MD, PhD, Lodewijka H. J. Holtkamp, MD, Roger F. Uren, MD, John F. Thompson, MD, Omgo E. Nieweg, MD, PhD

Published in: Annals of Surgical Oncology | Issue 2/2020

Login to get access

Abstract

Background

Sentinel node (SN) biopsy (SNB) is not routinely performed for melanoma patients with local recurrence (LR) or in-transit metastasis (ITM). This study aimed to describe the technique, findings, and prognostic value of this procedure, and the outcome for such patients at our institution.

Methods

Prospectively collected data were obtained from the Melanoma Institute Australia database. Patients who had SNB for LR or ITM between 1992 and 2015 were included in the study. Patient and primary tumor characteristics, lymphoscintigrams, SNB results, and follow-up data were analyzed.

Results

Overall, 7999 patients underwent SNB, 128 (1.6%) of whom met the selection criteria. The SNB procedure was performed for 85 of 1516 patients with LR (6%), 17 of 1671 patients with ITM from a known primary tumor (1%), and 26 of 170 patients who presented with ITM from an unknown primary site (15%). The SN identification rate was 100%. Metastatic melanoma was identified in an SN from 16 of the 128 patients (13%). Follow-up data were available for 114 patients. The false-negative rate was 27%. The SN-positive patients had significantly worse overall survival than the SN-negative patients, with respective 5-year survival rates of 54% and 81% (P = 0.01).

Conclusion

The SNB procedure was performed infrequently for LR or ITM. The SNs were positive for 13% of the patients with LR or ITM. Positive SNs were associated with worse overall survival. Despite the false-negative rate of 27%, the procedure yielded information that was relevant for staging and prognosis. The SNB procedure should be considered for patients with LR or ITM.
Literature
1.
Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370:599–609.CrossRef
2.
Yao KA, Hsueh EC, Essner R, Foshag LJ, Wanek LA, Morton DL. Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma? Ann Surg. 2003;238:743–7.CrossRef
3.
Beasley GM, Hu Y, Youngwirth L, et al. Sentinel lymph node biopsy for recurrent melanoma: a multicenter study. Ann Surg Oncol. 2017;24(9):2728–33.CrossRef
4.
Gipponi M, Solari N, Giovinazzo D, et al. The role of sentinel lymph node biopsy in patients with local recurrence or in-transit metastasis of melanoma. Anticancer Res. 2014;34:3197–203.
5.
Read RL, Haydu LE, Saw RPM, et al. In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy. Ann Surg Oncol. 2015;22:475–81.CrossRef
6.
Dong XD, Tyler D, Johnson JL, DeMatos P, Seigler HF. Analysis of prognosis and disease progression after local recurrence of melanoma. Cancer. 2000;88:1063–71.CrossRef
7.
Li L-XL, Scolyer RA, Ka VSK, et al. Pathologic review of negative sentinel lymph nodes in melanoma patients with regional recurrence. Am J Surg Pathol. 2003;27:1197–202.CrossRef
8.
Uren RF, Howman-Giles R, Chung D, Thompson JF. Guidelines for lymphoscintigraphy and F18 FDG PET scans in melanoma. J Surg Oncol. 2011;104:405–19.CrossRef
9.
Nieweg OE, Tanis PJ, Kroon BBR. The definition of a sentinel node. Ann Surg Oncol. 2001;8:538–41.CrossRef
10.
Gershenwald JE, Scolyer RA. Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond. Ann Surg Oncol. 2018;25:993–4.CrossRef
11.
IBM Corp. IBM SPSS statistics for windows. Armonk: IBM Corp.; 2016.
12.
R Core Team. R. A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2013.
13.
14.
Van Akkooi ACJ, De Wilt JHW, Verhoef C, et al. High positive sentinel node identification rate by EORTC melanoma group protocol: prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma. Eur J Cancer. 2006;42:372–80.CrossRef
15.
Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg. 2005;242:302–11.PubMedPubMedCentral
16.
Beasley GM, Speicher P, Sharma K, et al. Efficacy of repeat sentinel lymph node biopsy in patients who develop recurrent melanoma. J Am Coll Surg. 2014;218:686–92.CrossRef
17.
Coventry BJ, Chatterton B, Whitehead F, James C, Gill PG. Sentinel lymph node dissection and lymphatic mapping for local subcutaneous recurrence in melanoma treatment: longer-term follow-up results. Ann Surg Oncol. 2004;11(3 Suppl):203s–7s.CrossRef
18.
Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376:2211–22.CrossRef
19.
Estourgie SH, Nieweg OE, Valdés Olmos RA, Hoefnagel CA, Kroon BBR. Review and evaluation of sentinel node procedures in 250 melanoma patients with a median follow-up of 6 years. Ann Surg Oncol. 2003;10:681–8.CrossRef
20.
Gonzalez AB, Jakub JW, Harmsen WS, Suman VJ, Markovic SN. Status of the regional nodal basin remains highly prognostic in melanoma patients with in-transit disease. J Am Coll Surg. 2016;223:77–85.CrossRef
21.
Dewar DJ, Powell BWEM. Sentinel node biopsy in patients with in-transit recurrence of malignant melanoma. Br J Plast Surg. 2003;56:415–7.CrossRef
22.
Racz JM, Block MS, Baum CL, Jakub JW. Management of local or regional non-nodal disease. J Surg Oncol. 2019;119:187–99.CrossRef
23.
Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017;377:1824–35.CrossRef
24.
Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377:1813–23.CrossRef
25.
Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378:1789–1801.CrossRef
26.
Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17:757–67.CrossRef
27.
Veenstra HJ, Wouters MWJM, Kroon BBR, Valdés Olmos RA, Nieweg OE. Less false-negative sentinel node procedures in melanoma patients with experience and proper collaboration. J Surg Oncol. 2011;104:454–7.CrossRef
28.
Sakowska MM, Smith N, Coutts RJ. Twelve years’ experience of sentinel lymph node biopsy for melanoma at a rural New Zealand hospital. N Z Med J. 2014;127:12–22.PubMed
29.
Scolyer RA, Thompson JF, Li L-XL, et al (2004) Failure to remove true sentinel nodes can cause failure of the sentinel node biopsy technique: evidence from antimony concentrations in false-negative sentinel nodes from melanoma patients. Ann Surg Oncol. 11:174S–8S.CrossRef
Metadata
Title
Sentinel Node Biopsy for Melanoma Patients with a Local Recurrence or In-Transit Metastasis
Authors
Amanda A. G. Nijhuis, MD
Ivan D. de A. O. Santos Filho, MD, PhD
Lodewijka H. J. Holtkamp, MD
Roger F. Uren, MD
John F. Thompson, MD
Omgo E. Nieweg, MD, PhD
Publication date
01-02-2020
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 2/2020
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07699-9

Other articles of this Issue 2/2020

Annals of Surgical Oncology 2/2020 Go to the issue

Breast Oncology

Internal Mammary Sentinel Lymph Node Biopsy in Clinically Axillary Lymph Node-Positive Breast Cancer: Diagnosis and Implications for Patient Management

Gastrointestinal Oncology

Laparoscopic Suprapancreatic Lymph Node Dissection Using a Systematic Mesogastric Excision Concept for Gastric Cancer

ASO Author Reflections

ASO Author Reflections: More May Not Be Better

ASO Author Reflections

ASO Author Reflections: Regulation of Chemoresistance in Pancreatic Ductal Adenocarcinoma by Scavenger Receptor CD36

ASO Author Reflections

ASO Author Reflections: Delays in the Treatment of DCIS—What are the Costs?

Breast Oncology

Preoperative Delays in the Treatment of DCIS and the Associated Incidence of Invasive Breast Cancer